the abnormalities of the coagulation/fibrinolytic system that predispose to a procoagulant state.

### P-254
**EFFECTS OF TELMISARTAN ON ARTERIAL COMPLIANCE AND ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES PATIENTS WITH ESSENTIAL HYPERTENSION**

R. Asnay, P. Gosse, J. Topouchian, N'telu, S. Gray, A. Dudley. The Cardio Vascular Institute, Paris, France, 2Hôpital St André, Bordeaux, France, 3Gioxi Wellcome R&D, Greenford, United Kingdom

The effects of telmisartan on arterial compliance and endothelial function in subjects with type 2 diabetes suffering from light to moderate hypertension were investigated (protocol AZA30003). Twenty patients were randomised into a double-blind, placebo-controlled, 3 week cross-over study to receive either telmisartan (40 mg) or placebo after a 2 week placebo run-in period. The primary endpoint was the effect of telmisartan on arterial distensibility as measured by pulse wave velocity (carotid-femoral route) compared with placebo. Secondary endpoints included the effects of telmisartan on pulse wave velocity (carotid radial route) and further pulse wave analysis including measurements of augmentation index, ejection duration, first and second peak delays, subendocardial viability, brachial and central blood pressures. Insulin resistance and markers of endothelial function were also measured. Telmisartan significantly reduced the pulse wave velocity by the carotid femoral route. The mean adjusted treatment difference was −0.95 m/s (95% confidence intervals: −1.67, −0.23 m/s, p = 0.0002) after telmisartan administration. There was a significant effect of telmisartan compared with placebo. Details of these results and those of other secondary analyses will be presented at the meeting. Such findings show that telmisartan is effective at reducing arterial stiffness in hypertensive patients with type 2 diabetes mellitus.

Key Words: Diabetes, Hypertension, Angiotensin Antagonist

### P-255
**ATENOLOL AND NEVIBOLOL: COMPARATIVE INFLUENCE ON PARAMETERS OF THE CEREBRAL HEMODYNAMIC IN THE PATIENTS WITH ESSENTIAL HYPERTENSION**

L. P. Sydorchuk, V. K. Taschuk, I. V. Melnytsky, 1Bucovinian Medical Academy and Cardiocenter, Chernivtsi, Ukraine

With the purpose of assessing the influence of beta 1 – adrenoblockers (β1 – AB) upon the state of cerebral hemodynamic for the patients with essential hypertension (EH), acute pharmacological test with tenolol (Atenosan, “Sanofi”) and nebivolol (Nebilet, “Berlin Chemie”) was performed.

Fifty patients with EH stage 2 complicated with the heart failure (HF) stage 2 were observed. In the 1st group (26 patients) atenolol (50 mg daily) was administered for five days, and in the 2nd group of the patients (24 patients) nebivolol (5 mg daily) was taken for the same period. The condition of the blood supplying of the brain was examined by the computer Rheoencephalography (CREG) investigation, which was performed before the treatment, and on the fifth day of β1 – AB administration.

There were not significant differences in central hemodynamic parameters between the 1st and 2nd group of the patients before the treatment (p > 0.05). In the basin of a. carotis interna the blood filling was normal (p > 0.05), the tonus of the main brain vessels and arterioles was increased (p > 0.05), and the venous outflow was inconvenienced.

The blood filling of the main arteries had grown worse for 22% (p > 0.05), and the tonus was increased for 17% (p > 0.05) after atenolol administration. There was a fixed a tendency for improvement of these parameters for 7% and 10% (p > 0.05) respectively after nebivolol administration. Both atenolol and nebivolol administration made the venous outflow uncertainly worse (p > 0.05) on the fifth day of the acute pharmacological test.

Thus, it is more purposeful and safe to use nebivolol for the treatment of patients with essential hypertension and heart failure complicated with hypertensive dystonia of vertebrobasilar vessels.

Key Words: Side effects, Antihypertensive therapy, Calcium channel antagonists